Related Experiment Video
Updated: Feb 4, 2026

Targeted DNA Methylation Analysis by Next-generation Sequencing
Published on: February 24, 2015
Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor
Elena Helman1, Minh Nguyen2, Chris A Karlovich3
1Guardant Health Inc, Redwood City, CA.
Introduction:
The genomic alterations driving resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) are not well established, and collecting tissue biopsy samples poses potential complications from invasive procedures. Cell-free circulating DNA (cfDNA) testing provides a noninvasive approach to identify potentially targetable mechanisms of resistance. Here we utilized a 70-gene cfDNA next-generation sequencing test to interrogate pretreatment and progression samples from 77 EGFR-mutated non-small cell lung cancer (NSCLC) patients treated with a third-generation EGFR TKI.
Patients And Methods:
Rociletinib was evaluated in advanced or metastatic (second line or higher) disease with EGFR T790M-positive NSCLC in the TIGER-X (NCT01526928) and TIGER-2 (NCT02147990) studies. Plasma samples were collected at baseline and at the time of systemic progression while receiving rociletinib. The critical exons in 70 genes were sequenced in cfDNA isolated from plasma samples to elucidate a comprehensive genomic profile of alterations for each patient.
Results:
Plasma-based cfDNA analysis identified 93% of the initial EGFR activating and 85% of the EGFR T790M resistance mutations in pretreatment samples with detectable tumor DNA. Profiling of progression samples revealed significant heterogeneity, with different variant types (eg, mutations, amplifications, and fusions) detected in multiple genes (EGFR, MET, RB1) that may be driving resistance in patients. Novel alterations not previously described in association with resistance to third-generation TKIs were also detected, such as an NTRK1 fusion.
Conclusion:
cfDNA next-generation sequencing identified initial EGFR activating and secondary T790M resistance mutations in NSCLC patients with high sensitivity, predicted treatment response equivalent to tissue analysis, and identified multiple novel and established resistance alterations.
Insights
Cell-free DNA (cfDNA) testing noninvasively identifies EGFR mutations and resistance mechanisms in non-small cell lung cancer (NSCLC) patients treated with third-generation tyrosine kinase inhibitors (TKIs). This approach offers high sensitivity and reveals genomic heterogeneity at progression.
Area of Science:
- Genomics and Molecular Biology
- Oncology
- Translational Medicine
Background:
- Genomic alterations driving resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) are not fully understood.
- Tissue biopsies for resistance profiling are invasive and pose potential complications.
- Cell-free circulating DNA (cfDNA) offers a noninvasive alternative for identifying resistance mechanisms.
Purpose of the Study:
- To evaluate the utility of a 70-gene cfDNA next-generation sequencing (NGS) test for identifying genomic alterations in EGFR-mutated NSCLC patients.
- To analyze cfDNA from pretreatment and progression samples of patients treated with third-generation EGFR TKIs.
- To elucidate comprehensive genomic profiles and resistance mechanisms noninvasively.
Main Methods:
- Utilized a 70-gene cfDNA NGS test on plasma samples from 77 EGFR-mutated NSCLC patients.
- Samples were collected at baseline (pretreatment) and at the time of systemic progression.
- Sequenced critical exons in 70 genes to identify mutations, amplifications, and fusions.
Main Results:
- cfDNA analysis detected 93% of initial EGFR activating mutations and 85% of EGFR T790M resistance mutations in pretreatment samples.
- Progression samples revealed significant genomic heterogeneity, including alterations in EGFR, MET, and RB1.
- Novel resistance alterations, such as an NTRK1 fusion, were identified, expanding the known landscape of TKI resistance.
Conclusions:
- cfDNA NGS is a highly sensitive method for detecting both initial EGFR mutations and secondary T790M resistance mutations in NSCLC.
- Plasma-based cfDNA profiling demonstrated high sensitivity, comparable to tissue analysis, in predicting treatment response.
- This noninvasive approach successfully identified diverse and novel resistance alterations, aiding in personalized treatment strategies.
Related Concept Videos
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
DC Generator
Generation Time
Electric Generator: Alternator
The magnetic flux passing through the coil varies sinusoidally as the loop rotates inside the magnetic field. This...
Generation of Three-Phase Voltage
As the rotor...

